HOME > LATEST

LATEST

BUSINESS Padcev/Keytruda Wins US Nod for Perioperative Bladder Cancer Use

November 26, 2025
BUSINESS Otsuka Files Novel ADHD Drug Centanafadine in US

November 26, 2025
BUSINESS Novartis Eyes Broader Radioligand Therapy Footprint in Japan as Pluvicto Debuts

November 26, 2025
BUSINESS Eisai to Unify Global HR Framework by 2029 to Bolster Leqembi Growth

November 25, 2025
BUSINESS Marubeni Pharma Targets Doubling Profits by FY2035 with 2 New Deals Each Year

November 25, 2025
REGULATORY LDP, Ishin Start Framing Copay Models for OTC-Like Drugs: Bilateral Talks

November 25, 2025
BUSINESS Sanofi Seeks Age 60+ Access as Japan Plans NIP Addition of Efluelda for 75+

November 25, 2025
BUSINESS Kyowa Kirin Begins Japan PIII Trial of Infigratinib for Achondroplasia

November 25, 2025
BUSINESS Expert Expects New 21-Valent Pneumococcal Shot Capvaxive to Curb Invasive Disease

November 25, 2025
REGULATORY Label Updated for Gazyva and Imbruvica: PMDA

November 25, 2025
BUSINESS Otsuka’s Hypercholesterolemia Med Nexletol Hits Japan Shelves

November 25, 2025
REGULATORY Japan Finalizes Economic Package Positioning Pharma as “Core Industry”

November 25, 2025
REGULATORY Local Legislators Urge Routine HPV Shots for Males as LDP Group Renews Push

November 25, 2025
REGULATORY Japan to Launch Panel Next Year to Discuss Third-Party Access to Vaccination Database

November 25, 2025
REGULATORY Japan to Revise Guidance on Standards for Biological Raw Materials

November 25, 2025
REGULATORY Patient Groups Push Back against Delisting OTC-Like Drugs; Panel Leans Toward Higher Copays

November 21, 2025
REGULATORY Japan Approves Label Expansions for Braftovi, Augtyro, Uplizna, and More

November 21, 2025
REGULATORY Japan Panel OKs NIP Use of Maternal RSV Vaccine from FY2026

November 21, 2025
REGULATORY Japan to Add High-Dose Flu Vaccine to NIP for Adults Aged 75 and Over

November 21, 2025
BUSINESS Towa, Sawai Log H1 Sales Gains, but Overseas Woes and Litigation Drag on Profit

November 21, 2025

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch

By Ken Yoshino

Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…